# OnCo record quazar-aml-001 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/quazar-aml-001/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "quazar-aml-001", "NCT01757535" ;
  schema:name "QUAZAR AML-001"@en ;
  schema:alternateName "QUAZAR"@en ;
  schema:description "QUAZAR AML-001 showed that a tablet form of azacitidine taken as maintenance after chemotherapy helped older people with acute myeloid leukaemia live about ten months longer than placebo, and it became the first approved maintenance treatment for the disease."@en ;
  schema:url <https://onco.cc/trials/quazar-aml-001/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01757535> ;
  onco:status "positive" ;
  onco:tag "soc-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/aml-older-unfit/>, <https://onco.cc/cancers/leukaemia/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:drugs <https://onco.cc/drugs/azacitidine/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-quazar-aml-001-wei-nejm-2020/> .